The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases

Drug Metabolism and Disposition

Volumn 28, Issue 11, 2000, Pages 1385-1389

  Lautala, Pia ^a,c   Ethell, Brian T ^b   Taskinen, Jyrki ^a   Burchell, Brian ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ENTACAPONE; GLUCURONOSYLTRANSFERASE; PROPOFOL; RECOMBINANT ENZYME; TOLCAPONE;

ARTICLE; DRUG GLUCURONIDATION; HUMAN; HUMAN CELL; KIDNEY MICROSOME; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANIMALS; BENZOPHENONES; CATECHOLS; CELL LINE; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MICE; MICROSOMES, LIVER; NITROPHENOLS; RECOMBINANT PROTEINS;

EID: 0033786733     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tolcapone and fulminant hepatitis
2. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases
3. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
4. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications
5. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)
6. Human UGT2B7 catalyzes morphine glucuronidation
7. Pharmacokinetic-pharmacodynamic interaction betweeen the COMT inhibitor tolcapone and single-dose levodopa
8. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family
9. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol
10. A universal high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity
11. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates
12. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs
13. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase
14. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
15. Propofol; A review of its pharmacodynamic and pharmacokinetic properties and use as an intraveous anaesthetic
16. Glucuronidation of entacapone, nitecapone, tolcapone and some other nitrocatechols by rat liver microsomes
17. Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: Effect of different drugs
18. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene
19. Characterization and substrate specificity of UGT2B4(E458): A UDP-glucuronosyltransferase encoded by a polymorphic gene
20. PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors
21. Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides
22. Drug glucuronidation by human renal UDP-glucuronosyltransferases
23. Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors
24. Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans
25. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation
26. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans